1. Sun Pharmaceutical Industries
stock logo

67% Buy

Sun Pharmaceutical Industries Share Price

SUNPHARMA

₹1,786.05-₹41.40 (-2.27%) TodayLast updated on 07 Nov, 2024 | 13:00 IST

Sun Pharmaceutical Industries Share Price Chart

Please wait...
  • About Sun Pharmaceutical Industries
  • Fundamentals
  • Events
  • F&O (Option chain)
  • More
  • News

About Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Financials

arrow
Market cap
Market Cap Switch₹4,38,467 Crs
Open
₹1,845.00
Close
₹1,827.45
Circuit range
₹2,010.15 - ₹1,644.70
Day range
₹1,782.60 - ₹1,845.00
Year range
₹1,146.55 - ₹1,960.35
Volume
11,21,599
Avg. traded
₹1,801.95
Revenue (12m)
₹50,308 Crs
Sun Pharmaceutical Industries

Sun Pharmaceutical Industries Ltd is the world’s fourth-largest specialty generic pharmaceutical company. With a network of over 40 manufacturing facilities, the company distributes medicines to more than over 100 countries worldwide. The company has a global employee base of over 41,000.

The company’s recent acquisition of Concert Pharmaceuticals Inc in the United States has granted it access to the late-stage asset deuruxolitinib, which has completed Phase-3 studies for treating alopecia areata. Founded in 1983, Sun Pharma has a market capitalisation of ₹2,98,705 crore as of December 19, 2023. Sun Pharma share price has gained 114% in the last 3 years.

Business portfolio

The company manufactures and markets a wide range of pharmaceutical formulations, which include generics, branded generics, over-the-counter, antiretrovirals, intermediates and active pharmaceutical ingredients. In specialty medications, Sun Pharma has a portfolio of patent-protected drugs. With focus on dermatology, ophthalmology and oncology, the company aims to improve patient outcomes by addressing unmet medical needs and enhancing convenience through diverse dosage forms.

Sun Pharma provides high-quality generic and branded medicines to patients and healthcare professionals in over 100 countries. These medicines are available in tablets, capsules, injectables, inhalers, ointments, creams and liquids.

The therapeutic segments covered by the company’s portfolio includes psychiatry, anti-infectives, neurology, cardiology, orthopaedics, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Sun Pharma consistently ranks among the leading companies in these therapy areas. Presently, it’s one of the top companies in the United States, having introduced a number of speciality items.

When it comes to over-the-counter medications, Sun Pharma’s range is diverse. Its flagship OTC brands such as Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics) are available globally.

With regards to active pharmaceutical ingredients (APIs), Sun Pharma began producing them in 1995. The company manufactures more than 300 APIs that are sold in over 60 countries. These are manufactured in 14 sites spread across India, Hungary, the United States, Israel and Australia.

Sun Pharma provides a selection of antiretroviral (ARV) drugs that have been prequalified by the WHO. The company works with groups like the Clinton Health Access Initiative (CHAI) to lower the cost of triple medication combinations and provides ARVs to various National AIDS treatment programmes in Africa.

Bioequivalent ARV medications and APIs are produced at WHO-prequalified facilities in India, a PIC/S-approved facility in South Africa and a plant in Russia, all of which are part of Sun Pharma’s portfolio.

Financial highlights

In FY23, the total income of the company stood at ₹44,520 crore, compared to ₹39,576 crore in the previous fiscal year. The company’s net profit after minority interest for FY23 was ₹8,473.6 crore, compared to ₹3,272.7 crore in FY22. Its earnings per share (EPS) for FY23 stood at ₹35.3, compared to ₹13.6 in FY22. The company made a capital expenditure of ₹60 crore in FY23 as against ₹87 crore in FY22. The research and development (R&D) expenditure stood at ₹2,367.6 crore in FY23.

Sun Pharmaceutical Industries Key indicators

arrow
52 week high
₹1,960.35
52 week low
₹1,146.55
P/E ratio
39.62
P/B ratio
6.26
ROE
12.05%
ROCE
12.81%
Dividend yield
0.75%
Debt/Equity ratio
0.47
EPS
11.91

Learn more

Investment checklist: (5/6)
arrow
check status

Equity returns

check status

Dividend returns

check status

Safety factor

check status

Growth factor

check status

Debt vs Equity

check status

Profit factor

The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily

Analyst ratings:

Buy

arrow

Buy

67%

Hold

24%

Sell

9%

This analysis is based on the reviews of 33 experts in the last 7 days

Brands by Sun Pharmaceutical Industries

arrow
brand logo

SPARC

Sun Pharmaceutical Industries Fundamentals

Sun Pharmaceutical Industries Financial Ratios

arrow
  • Profitability

  • Operational

  • Valuation

Operating profit margin

29.86%

Net profit margin

14.1%

ROE

12.05%

ROA

6.86%

ROCE

12.81%

Learn more

Sun Pharmaceutical Industries Shareholder returns

arrow
1 day
+1.32%
1 week
-1.33%
1 month
-4.32%
3 months
+7.02%
1 year
+58.91%
3 years
+129.74%
5 years
+327.07%

Sun Pharmaceutical Industries Share Price history

arrow
DayOpenCloseChange %
Wed, Nov 6 2024
₹1,815.55
₹1,827.45
+1.32%
Tue, Nov 5 2024
₹1,805.00
₹1,803.60
-0.29%
Mon, Nov 4 2024
₹1,845.00
₹1,808.90
-2.66%
Fri, Nov 1 2024
₹1,860.00
₹1,858.40
+0.51%
Thu, Oct 31 2024
₹1,860.00
₹1,848.90
-0.17%
Wed, Oct 30 2024
₹1,868.50
₹1,852.10
-1.04%
Tue, Oct 29 2024
₹1,922.00
₹1,871.60
-1.64%
Mon, Oct 28 2024
₹1,863.20
₹1,902.90
+2.28%

Sun Pharmaceutical Industries Shareholding Pattern

arrow

Promoters (54.48%)

Mutual Funds (12.11%)

Retail and other (8.9%)

Foreign institutions-FII (18.01%)

Other domestic institutions (6.5%)

Promoters

Learn more

Events

Corporate actions

arrow
  • Dividend • ₹5/share

    Ex date 12 Jul 2024

    expand tab
  • Dividend • ₹8.5/share

    Ex date 09 Feb 2024

    expand tab
  • Dividend • ₹4/share

    Ex date 28 Jul 2023

    expand tab
  • Dividend • ₹7.5/share

    Ex date 08 Feb 2023

    expand tab
  • Dividend • ₹3/share

    Ex date 19 Aug 2022

    expand tab
  • Dividend • ₹7/share

    Ex date 09 Feb 2022

    expand tab

Learn more

FAQs on Sun Pharmaceutical Industries